WO2004076615A3 - Composes prtobiotiques immunomodulateurs - Google Patents

Composes prtobiotiques immunomodulateurs Download PDF

Info

Publication number
WO2004076615A3
WO2004076615A3 PCT/DK2004/000138 DK2004000138W WO2004076615A3 WO 2004076615 A3 WO2004076615 A3 WO 2004076615A3 DK 2004000138 W DK2004000138 W DK 2004000138W WO 2004076615 A3 WO2004076615 A3 WO 2004076615A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
intracellular
bifidobacterium
lactobacillus
polypeptides
Prior art date
Application number
PCT/DK2004/000138
Other languages
English (en)
Other versions
WO2004076615A9 (fr
WO2004076615A2 (fr
Inventor
Hans Israelsen
Soeren Michael Madsen
Jacob Glenting
Astrid Vrang
Mette Rindom Noerrelykke
Anne Maria Hansen
Siv Elsa Ingegerd Ahrne
Goeran Molin
Peter Ravn
Hans Christian Beck
Original Assignee
Bioneer As
Probi Ab
Hans Israelsen
Soeren Michael Madsen
Jacob Glenting
Astrid Vrang
Mette Rindom Noerrelykke
Anne Maria Hansen
Siv Elsa Ingegerd Ahrne
Goeran Molin
Peter Ravn
Hans Christian Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer As, Probi Ab, Hans Israelsen, Soeren Michael Madsen, Jacob Glenting, Astrid Vrang, Mette Rindom Noerrelykke, Anne Maria Hansen, Siv Elsa Ingegerd Ahrne, Goeran Molin, Peter Ravn, Hans Christian Beck filed Critical Bioneer As
Publication of WO2004076615A2 publication Critical patent/WO2004076615A2/fr
Publication of WO2004076615A9 publication Critical patent/WO2004076615A9/fr
Publication of WO2004076615A3 publication Critical patent/WO2004076615A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0067—Oxidoreductases (1.) acting on hydrogen as donor (1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/02—Phosphotransferases with a carboxy group as acceptor (2.7.2)
    • C12Y207/02003—Phosphoglycerate kinase (2.7.2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01001—Triose-phosphate isomerase (5.3.1.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes de modulation (i) d'une réponse immunitaire et/ou (ii) de la quantité et/ou de la composition de mucines des muqueuses, consistant à mettre en contact une partie formant cellule d'un tissu lymphoïde associé à des muqueuses (MALT), ou une cellule épithéliale avec un polypeptide de surface d'une cellule microbienne. La modulation de la réponse immunitaire fait intervenir de préférence une ou plusieurs cytokines. Le polypeptide de surface de cellule microbienne est de préférence un polypeptide obtenu à partir de Lactobacillus ou de Bifidobacterium. Curieusement, on a constaté que les enzymes intracellulaires agissant dans les voies métaboliques de Lactobacillus et de Bifidobacterium, ou bien des polypeptides sensiblement identiques à de tels enzymes intracellulaires, étaient transportés à la surface de la cellule où ils pouvaient être au moins partiellement exposés au milieu extra-cellulaire. Par voie de conséquence, les polypeptides de surface cellulaire préférés ont des équivalents intracellulaires (c'est-à-dire associés au cytoplasme) agissant dans les voies métaboliques, telles que la glycolyse, dans les espèces probiotiques de Lactobacillus et/ou de Bifidobacterium. Les polypetides associés à la surface et leurs équivalents intracellulaires partagent une suite importante de résidus d'acides aminés consécutifs, mais sont situées dans des parties différentes de la cellule.
PCT/DK2004/000138 2003-02-27 2004-02-27 Composes prtobiotiques immunomodulateurs WO2004076615A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44984003P 2003-02-27 2003-02-27
US60/449,840 2003-02-27
DKPA200300315 2003-02-27
DKPA200300315 2003-02-27
US48215603P 2003-06-25 2003-06-25
US60/482,156 2003-06-25

Publications (3)

Publication Number Publication Date
WO2004076615A2 WO2004076615A2 (fr) 2004-09-10
WO2004076615A9 WO2004076615A9 (fr) 2004-10-14
WO2004076615A3 true WO2004076615A3 (fr) 2004-12-09

Family

ID=32930957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000138 WO2004076615A2 (fr) 2003-02-27 2004-02-27 Composes prtobiotiques immunomodulateurs

Country Status (1)

Country Link
WO (1) WO2004076615A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254058A1 (en) * 2004-12-14 2008-10-16 Alk-Abello A/S Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
BRPI0616962B8 (pt) 2005-10-06 2021-05-25 Probi Ab uso de lactobacillus para o tratamento de doenças autoimunes
EA016734B1 (ru) * 2006-12-21 2012-07-30 Калпис Ко., Лтд. СРЕДСТВА ДЛЯ СТИМУЛЯЦИИ ПРОДУЦИРОВАНИЯ IgA НА ОСНОВЕ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS И ШТАММ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS CP1750 FERM BP-10532
PL2134833T3 (pl) 2007-03-28 2016-09-30 Probiotyczny szczep Bifidobacterium
AU2008231467A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic Bifidobacterium strains
FR2922450B1 (fr) * 2007-10-19 2014-06-13 Lallemand Sas Utilisation de bacteries lactique pour la prevention et/ou le traitement de pathologies cutanees
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
WO2013099883A1 (fr) * 2011-12-28 2013-07-04 株式会社山田養蜂場本社 Nouvelle bactérie lactique ayant une activité favorisant la production d'iga, et son utilisation
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
WO2017058175A1 (fr) 2015-09-29 2017-04-06 Kimberly-Clark Worldwide, Inc. Composition synergique pour le maintien d'un équilibre sain de la microflore
RU2763311C2 (ru) * 2017-01-12 2021-12-28 Проби Аб Пробиотические композиции и их применение
WO2018183685A1 (fr) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Méthodes de régulation de l'expression génique dans une cellule
JP2022516703A (ja) * 2019-01-06 2022-03-02 セカンド ゲノム インコーポレイテッド 免疫療法のための微生物由来のペプチドおよびタンパク質
CN110144311B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN110184214B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN112501049B (zh) * 2020-10-28 2022-04-19 石河子大学 产转糖基活性β-半乳糖苷酶的开菲尔乳杆菌及制备的β-半乳糖苷酶生产低聚半乳糖的方法
CN114381411B (zh) * 2022-03-23 2022-05-27 山东中科嘉亿生物工程有限公司 乳酸乳球菌jyll-60及其在制备提高免疫力的产品上的应用
CN116445321B (zh) * 2022-12-13 2023-11-24 广西爱生生命科技有限公司 降核苷降血尿酸罗伊氏乳杆菌a21160及其应用
CN116694530B (zh) * 2023-06-28 2023-11-07 北京量化健康科技有限公司 一种乳杆菌组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012506A1 (fr) * 2000-08-08 2002-02-14 Genesis Research And Development Corporation Limited Polynucleotides et polypeptides lactobacillus rhamnosus et methodes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012506A1 (fr) * 2000-08-08 2002-02-14 Genesis Research And Development Corporation Limited Polynucleotides et polypeptides lactobacillus rhamnosus et methodes d'utilisation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BORRUEL N ET AL: "INCREASED MUCOSAL TUMOUR NECROSIS FACTOR ALPHA PRODUCTION IN CROHN'S DISEASE CAN BE DOWNREGULATED EX VIVO BY PROBIOTIC BACTERIA", GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 51, 2002, pages 659 - 664, XP008023641, ISSN: 0017-5749 *
DATABASE EMBL [online] 6 February 2003 (2003-02-06), KLEEREBEZEM M ET AL: "Lactobacillus plantarum strain WCFS1 complete genome; segment 3/11", XP002298978, retrieved from EBI Database accession no. AL935254 *
HUGHES M J G ET AL: "Identification of major outer surface proteins of Streptococcus agalactiae", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 70, no. 3, March 2002 (2002-03-01), pages 1254 - 1259, XP002254598, ISSN: 0019-9567 *
KLEEREBEZEM MICHIEL ET AL: "Complete genome sequence of Lactobacillus plantarum WCFS1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 1990 - 1995, XP002285325, ISSN: 0027-8424 *
PANCHOLI V: "Multifunctional alpha-enolase: Its role in diseases", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 58, no. 7, June 2001 (2001-06-01), pages 902 - 920, XP002288673, ISSN: 1420-682X *
ULRICH R L ET AL: "Cloning and expression analysis of the 28 kDa protein from Lactobacillus delbrueckii subsp. lactis ATCC 4797 hypothesized to influence lactacin B production", JOURNAL OF APPLIED MICROBIOLOGY, vol. 91, no. 6, December 2001 (2001-12-01), pages 1067 - 1073, XP002288674, ISSN: 1364-5072 *

Also Published As

Publication number Publication date
WO2004076615A9 (fr) 2004-10-14
WO2004076615A2 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2004076615A3 (fr) Composes prtobiotiques immunomodulateurs
Singh et al. Growth and bioactive peptides production potential of Lactobacillus plantarum strain C2 in soy milk: A LC-MS/MS based revelation for peptides biofunctionality
Nongonierma et al. Quinoa (Chenopodium quinoa Willd.) protein hydrolysates with in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant properties
Yang et al. Amino acid composition, molecular weight distribution and antioxidant activity of protein hydrolysates of soy sauce lees
Li et al. Purification and identification of novel peptides with inhibitory effect against angiotensin I-converting enzyme and optimization of process conditions in milk fermented with the yeast Kluyveromyces marxianus
Brandelli et al. Whey as a source of peptides with remarkable biological activities
Sanchez-Rivera et al. Bioavailability and kinetics of the antihypertensive casein-derived peptide HLPLP in rats
MX2022005412A (es) Composiciones que comprenden cepas bacterianas para uso para aumentar la biodisponibilidad de aminoacidos derivados de proteinas.
Chen et al. Preparation and functional evaluation of collagen oligopeptide-rich hydrolysate from fish skin with the serine collagenolytic protease from Pseudoalteromonas sp. SM9913
MX2010014091A (es) Composiciones de hidrolizado de proteinas estables en condiciones acidas.
IN2014CN02050A (fr)
Chanalia et al. Extraction, purification and characterization of low molecular weight Proline iminopeptidase from probiotic L. plantarum for meat tenderization
EP0786473A3 (fr) Composition de protéine basique, composition de peptide basique et leur application
Zhao et al. Preparation and radical scavenging activity of papain-catalyzed casein plasteins
WO2006073976A3 (fr) Compositions, procedes et kits permettant d'ameliorer l'expression, la solubilite et l'isolation des proteines
BRPI0507623A (pt) peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
US10604780B2 (en) Low gluten yeast hydrolysates
US9403870B2 (en) Methods of phosvitin extraction and phosphopeptide preparation from egg yolk
Meshginfar et al. Physicochemical, antioxidant, calcium binding, and angiotensin converting enzyme inhibitory properties of hydrolyzed tomato seed proteins
Inoue et al. Release of antihypertensive peptides in miso paste during its fermentation, by the addition of casein
ATE493503T1 (de) Verfahren zur fermentativen herstellung von proteinen
Abd Rashid et al. Evaluation of antioxidant and antibacterial activities of fish protein hydrolysate produced from Malaysian fish sausage (Keropok Lekor) by-products by indigenous Lactobacillus casei fermentation
Holder et al. Selective isolation of angiotensin-I-converting enzyme-inhibitory peptides from micellar casein and β-casein hydrolysates via ultrafiltration
Yousefi et al. Production of angiotensin‐converting enzyme inhibitory peptides in Iranian ultrafiltered white cheese prepared with Lactobacillus brevis KX572382

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: SEQUENCE LISTING, ADDED, (1-27 PAGES)

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase